BR9611626A - Formulações farmacéuticas - Google Patents

Formulações farmacéuticas

Info

Publication number: BR9611626A
Authority: BR; Brazil
Prior art keywords: pharmaceutical formulations; formulations; pharmaceutical
Prior art date: 1995-11-21

Application number

BR9611626A

Other languages

English (en)

Inventor

Ross James Macrae

Janet Sarah Smith

Original Assignee

Pfizer Res & Dev

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-11-21

Filing date

1996-11-11

Publication date

1999-06-01

1996-11-11 Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev

1999-06-01 Publication of BR9611626A publication Critical patent/BR9611626A/pt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

BR9611626A 1995-11-21 1996-11-11 Formulações farmacéuticas BR9611626A (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9523752.5A GB9523752D0 (en)	1995-11-21	1995-11-21	Pharmaceutical formulations
PCT/EP1996/005020 WO1997018814A1 (en)	1995-11-21	1996-11-11	Pharmaceutical formulations

Publications (1)

Publication Number	Publication Date
BR9611626A true BR9611626A (pt)	1999-06-01

Family

ID=10784188

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR9611626A BR9611626A (pt)	1995-11-21	1996-11-11	Formulações farmacéuticas

Country Status (29)

Country	Link
EP (1)	EP0862437A1 (pt)
JP (1)	JPH10513481A (pt)
KR (1)	KR19990071505A (pt)
CN (1)	CN1215993A (pt)
AP (1)	AP718A (pt)
AR (1)	AR004335A1 (pt)
AU (1)	AU709560B2 (pt)
BG (1)	BG102438A (pt)
BR (1)	BR9611626A (pt)
CA (1)	CA2232715A1 (pt)
CO (1)	CO4480020A1 (pt)
CZ (1)	CZ155498A3 (pt)
GB (1)	GB9523752D0 (pt)
HR (1)	HRP960554A2 (pt)
HU (1)	HUP9903734A3 (pt)
IS (1)	IS4706A (pt)
MA (1)	MA26410A1 (pt)
MX (1)	MX9804008A (pt)
NO (1)	NO982302L (pt)
NZ (1)	NZ322053A (pt)
OA (1)	OA10687A (pt)
PE (1)	PE22898A1 (pt)
PL (1)	PL326981A1 (pt)
SK (1)	SK63098A3 (pt)
TN (1)	TNSN96141A1 (pt)
TR (1)	TR199800902T2 (pt)
WO (1)	WO1997018814A1 (pt)
YU (1)	YU62096A (pt)
ZA (1)	ZA969722B (pt)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR9813699A (pt) *	1997-12-16	2000-10-10	Pfizer Prod Inc	Combinação eficaz para o tratamento da impotência
CN1203846C (zh)	1998-03-19	2005-06-01	布里斯托尔-迈尔斯斯奎布公司	高溶解性药物的双相控释递送***和方法
GT199900061A (es) *	1998-05-15	2000-10-14	Pfizer	Formulaciones farmaceuticas.
EP0987020A1 (en) *	1998-09-04	2000-03-22	Pharma Pass LLC	Metoprolol composition and processes for manufacturing the same
EP0974343B1 (en) *	1998-07-22	2004-09-29	Pharma Pass II LLC	Process for manufacturing a solid metoprolol composition
CO5140079A1 (es) *	1998-10-14	2002-03-22	Novartis Ag	Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
UA67802C2 (uk) *	1998-10-23	2004-07-15	Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А.	Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
US20030059467A1 (en) *	2001-09-14	2003-03-27	Pawan Seth	Pharmaceutical composition comprising doxasozin
US7612112B2 (en)	2001-10-25	2009-11-03	Depomed, Inc.	Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en)	2001-10-25	2004-04-20	Depomed, Inc.	Optimal polymer mixtures for gastric retentive tablets
TWI312285B (en)	2001-10-25	2009-07-21	Depomed Inc	Methods of treatment using a gastric retained gabapentin dosage
US8329217B2 (en)	2001-11-06	2012-12-11	Osmotica Kereskedelmi Es Szolgaltato Kft	Dual controlled release dosage form
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2005037247A2 (en) *	2003-10-17	2005-04-28	Ranbaxy Laboratories Limited	Oral matrix formulations of doxazosin
US20050255157A1 (en) *	2004-05-11	2005-11-17	Glenmark Pharmaceuticals Limited	Sustained release, mucoadhesive vaginal pharmaceutical compositions
KR100574554B1 (ko) *	2004-05-28	2006-04-27	한미약품 주식회사	니아신의 경구투여용 서방성 조성물
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
KR100679111B1 (ko) *	2004-11-20	2007-02-07	대우약품공업주식회사	독사조신을 포함하는 서방성 정제
CA2619035A1 (en) *	2005-08-22	2007-03-01	Novartis Ag	Pharmaceutical compositions
US20090176882A1 (en)	2008-12-09	2009-07-09	Depomed, Inc.	Gastric retentive gabapentin dosage forms and methods for using same
DE602007012236D1 (de)	2006-04-26	2011-03-10	Supernus Pharmaceuticals Inc	Oxcarbazepin-zubereitungen für kontrollierte freisetzung mit sigmoidalem freisetzungsprofil
PE20110235A1 (es)	2006-05-04	2011-04-14	Boehringer Ingelheim Int	Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
NZ573360A (en)	2006-05-04	2012-08-31	Boehringer Ingelheim Int	Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
CN100396282C (zh) *	2006-07-25	2008-06-25	山东省医药工业研究所	甲磺酸多沙唑嗪缓释胶囊及制备方法
SA07280459B1 (ar) *	2006-08-25	2011-07-20	بيورديو فارما إل. بي.	أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US8372432B2 (en)	2008-03-11	2013-02-12	Depomed, Inc.	Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
CN102105136B (zh)	2008-03-11	2014-11-26	蒂宝制药公司	包含非-阿片类止痛剂和阿片类止痛剂的组合的胃滞留型缓释剂型
AR071175A1 (es)	2008-04-03	2010-06-02	Boehringer Ingelheim Int	Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
KR20190016601A (ko)	2008-08-06	2019-02-18	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101004205B1 (ko)	2008-12-17	2010-12-24	동아제약주식회사	유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
WO2010092125A1 (en)	2009-02-13	2010-08-19	Boehringer Ingelheim International Gmbh	Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
US9901551B2 (en)	2009-04-20	2018-02-27	Ambra Bioscience Llc	Chemosensory receptor ligand-based therapies
US8828953B2 (en)	2009-04-20	2014-09-09	NaZura BioHealth, Inc.	Chemosensory receptor ligand-based therapies
AU2010239311B2 (en)	2009-04-20	2014-05-22	Elcelyx Therapeutics, Inc.	Chemosensory receptor ligand-based therapies
JP2013512229A (ja)	2009-11-27	2013-04-11	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	遺伝子型が同定された糖尿病患者のリナグリプチン等のｄｄｐ−ｉｖ阻害薬による治療
US9198861B2 (en)	2009-12-22	2015-12-01	Mallinckrodt Llc	Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US20110150989A1 (en) *	2009-12-22	2011-06-23	Mallinkckrodt Inc.	Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
NZ602921A (en)	2010-05-05	2016-01-29	Boehringer Ingelheim Int	Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor
WO2012006398A2 (en)	2010-07-09	2012-01-12	Bhv Pharma, Inc.	Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin
EP2630491A4 (en)	2010-10-19	2014-08-27	Elcelyx Therapeutics Inc	THERAPIES BASED ON CHEMOSOUS RECEPTOR LIGANDS
US9034883B2 (en)	2010-11-15	2015-05-19	Boehringer Ingelheim International Gmbh	Vasoprotective and cardioprotective antidiabetic therapy
US20120177730A1 (en)	2011-01-07	2012-07-12	Elcelyx Therapeutics, Inc.	Chemosensory Receptor Ligand-Based Therapies
CN102058555A (zh) *	2011-01-13	2011-05-18	北京汇诚瑞祥医药技术有限公司	一种多沙唑嗪控释片
UY33937A (es)	2011-03-07	2012-09-28	Boehringer Ingelheim Int	Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
CN102188431A (zh) *	2011-05-09	2011-09-21	浙江九旭药业有限公司	甲磺酸多沙唑嗪缓释片及其制备方法
US8741885B1 (en)	2011-05-17	2014-06-03	Mallinckrodt Llc	Gastric retentive extended release pharmaceutical compositions
US8858963B1 (en)	2011-05-17	2014-10-14	Mallinckrodt Llc	Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US9050335B1 (en)	2011-05-17	2015-06-09	Mallinckrodt Llc	Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US20130143867A1 (en)	2011-12-02	2013-06-06	Sychroneuron Inc.	Acamprosate formulations, methods of using the same, and combinations comprising the same
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
WO2013158928A2 (en)	2012-04-18	2013-10-24	Elcelyx Therapeutics, Inc.	Chemosensory receptor ligand-based therapies
WO2013171167A1 (en)	2012-05-14	2013-11-21	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP2016520653A (ja)	2013-06-05	2016-07-14	シンクロニューロンインコーポレイテッド	アカンプロサート製剤、それを用いる方法、およびそれを含む合剤
US9526728B2 (en)	2014-02-28	2016-12-27	Boehringer Ingelheim International Gmbh	Medical use of a DPP-4 inhibitor
CN105616378A (zh) *	2014-10-31	2016-06-01	康普药业股份有限公司	一种氟康唑胶囊及其制备方法
EP3468562A1 (en)	2016-06-10	2019-04-17	Boehringer Ingelheim International GmbH	Combinations of linagliptin and metformin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1198386B (it) *	1982-07-06	1988-12-21	Lepetit Spa	Un prodotto a rilascio protratto contenente il suloctidile
US4765989A (en) *	1983-05-11	1988-08-23	Alza Corporation	Osmotic device for administering certain drugs
US4837111A (en) *	1988-03-21	1989-06-06	Alza Corporation	Dosage form for dispensing drug for human therapy
IL92966A (en) *	1989-01-12	1995-07-31	Pfizer	Hydrogel-operated release devices
ATE111351T1 (de) *	1990-07-23	1994-09-15	Alza Corp	Oral anzuwendende osmotische vorrichtung zur abgabe von nicotin.

1995
- 1995-11-21 GB GBGB9523752.5A patent/GB9523752D0/en active Pending
1996
- 1996-11-11 PL PL96326981A patent/PL326981A1/xx unknown
- 1996-11-11 EP EP96938215A patent/EP0862437A1/en not_active Withdrawn
- 1996-11-11 CZ CZ981554A patent/CZ155498A3/cs unknown
- 1996-11-11 CN CN96198486A patent/CN1215993A/zh active Pending
- 1996-11-11 SK SK630-98A patent/SK63098A3/sk unknown
- 1996-11-11 HU HU9903734A patent/HUP9903734A3/hu unknown
- 1996-11-11 JP JP9519364A patent/JPH10513481A/ja active Pending
- 1996-11-11 KR KR1019980703777A patent/KR19990071505A/ko not_active Application Discontinuation
- 1996-11-11 AU AU75721/96A patent/AU709560B2/en not_active Ceased
- 1996-11-11 BR BR9611626A patent/BR9611626A/pt not_active Application Discontinuation
- 1996-11-11 CA CA002232715A patent/CA2232715A1/en not_active Abandoned
- 1996-11-11 NZ NZ322053A patent/NZ322053A/xx unknown
- 1996-11-11 TR TR1998/00902T patent/TR199800902T2/xx unknown
- 1996-11-11 WO PCT/EP1996/005020 patent/WO1997018814A1/en not_active Application Discontinuation
- 1996-11-20 MA MA24397A patent/MA26410A1/fr unknown
- 1996-11-20 TN TNTNSN96141A patent/TNSN96141A1/fr unknown
- 1996-11-20 YU YU62096A patent/YU62096A/sh unknown
- 1996-11-20 AR ARP960105252A patent/AR004335A1/es unknown
- 1996-11-20 ZA ZA9609722A patent/ZA969722B/xx unknown
- 1996-11-20 PE PE1996000831A patent/PE22898A1/es not_active Application Discontinuation
- 1996-11-21 HR HR9523752.5A patent/HRP960554A2/hr not_active Application Discontinuation
- 1996-11-21 AP APAP/P/1996/000883A patent/AP718A/en active
- 1996-11-21 CO CO96061449A patent/CO4480020A1/es unknown
1998
- 1998-03-31 IS IS4706A patent/IS4706A/is unknown
- 1998-05-08 BG BG102438A patent/BG102438A/xx unknown
- 1998-05-19 OA OA9800058A patent/OA10687A/en unknown
- 1998-05-20 MX MX9804008A patent/MX9804008A/es unknown
- 1998-05-20 NO NO982302A patent/NO982302L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
HUP9903734A2 (hu)	2000-03-28
CO4480020A1 (es)	1997-07-09
WO1997018814A1 (en)	1997-05-29
YU62096A (sh)	1999-03-04
CZ155498A3 (cs)	1999-03-17
NZ322053A (en)	1999-11-29
AP9600883A0 (en)	1997-01-31
CA2232715A1 (en)	1997-05-29
CN1215993A (zh)	1999-05-05
ZA969722B (en)	1998-05-20
OA10687A (en)	2002-11-27
BG102438A (en)	1999-01-29
MX9804008A (es)	1998-09-30
HRP960554A2 (en)	1998-02-28
KR19990071505A (ko)	1999-09-27
NO982302L (no)	1998-07-17
AU7572196A (en)	1997-06-11
NO982302D0 (no)	1998-05-20
JPH10513481A (ja)	1998-12-22
AR004335A1 (es)	1998-11-04
GB9523752D0 (en)	1996-01-24
PL326981A1 (en)	1998-11-09
TR199800902T2 (xx)	1998-09-21
AU709560B2 (en)	1999-09-02
EP0862437A1 (en)	1998-09-09
TNSN96141A1 (fr)	2005-03-15
AP718A (en)	1999-01-06
PE22898A1 (es)	1998-05-07
MA26410A1 (fr)	2004-12-20
SK63098A3 (en)	1999-05-07
IS4706A (is)	1998-03-31
HUP9903734A3 (en)	2000-04-28

Legal Events

Date	Code	Title
2002-05-07	FB34	Technical and formal requirements: requirement - article 34 of industrial property law
2002-12-10	FA14	Dismissal: dismissal - article 34 of industrial property law
2020-09-24	B11T	Dismissal of application maintained [chapter 11.20 patent gazette]

Publication	Publication Date	Title
BR9610153A (pt)	1999-01-05	Formulações farmacêuticas
BR9611626A (pt)	1999-06-01	Formulações farmacéuticas
NO20021172L (no)	1996-12-23	Farmasöytisk sammensetning
DK1093815T3 (da)	2005-04-25	Oral 2-methyl-thieno-benzodiazepinformulering
DE69530325D1 (de)	2003-05-15	Aerosol-arzneiformulierungen
BR9611367A (pt)	1999-02-23	Formulação farmacêutic liofilizada estável
ID24654A (id)	2000-07-27	Formulasi farmasi omeprazola
NO981008D0 (no)	1998-03-06	Farmasöytisk formulering
NO954486D0 (no)	1995-11-08	Farmasöytiske formuleringsgrunnlag
BR9610214A (pt)	1999-06-15	Compostos farmacéuticos
ITMI951395A0 (it)	1995-06-29	Formulazioni di f-silicone
ID16781A (id)	1997-11-13	Formulasi-formulasi farmasi
DE69614407T2 (de)	2002-05-29	Pharmazeutische zusammensetzungen
LV11727A (lv)	1997-04-20	Farmaceitiska kompozicija
TR199501082A2 (tr)	1996-06-21	Farmasötik formülasyonlar.
ITMI941169A0 (it)	1994-06-06	Formulazioni farmaceutiche
FI973280A0 (fi)	1997-08-08	Farmaseuttinen koostumus
FI973230A (fi)	1997-08-05	Uusi farmaseuttinen formulaatio
FI951155A0 (fi)	1995-03-13	Farmaseuttinen valmiste
NO965448L (no)	1997-06-20	Farmasöytiske forbindelser
BR9605777A (pt)	1998-08-25	Composição farmacêutica
NO964309D0 (no)	1996-10-10	Farmasöytisk sammensetning
SE9502453D0 (sv)	1995-07-06	Drug formulations
DE29618094U1 (de)	1998-02-12	Pharmazeutisches Präparat
SE9404467D0 (sv)	1994-12-22	Drug formulations